LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Начало・Списък с акции・Gilead Sciences Inc.

Gilead Sciences Inc.

Затворен

СекторЗдравеопазване

129.61 0.07

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

129.13

Максимум

130.97

Ключови измерители
By Trading Economics
Приходи	-162M 2B
Продажби	-965M 7B
P/E Средно за сектора	18.191 51.415
EPS	2.03
Дивидентна доходност	2.43
Марж на печалбата	29.037
Служители	17,000
EBITDA	18M 2.4B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+23.34% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	2.43% 2.34%
Следващи печалби	6.08.2026 г.
Следваща дата на дивидент	29.06.2026 г.
Следваща дата на екс-дивидент	15.06.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.1B 166B
Предишно отваряне	129.54
Предишно затваряне	129.61

Настроения в новините

By Acuity

28%

72%

48 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

97.33 / 103.17 Подкрепа & съпротива

Gilead Sciences Inc. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.05.2026 г., 20:49 ч. UTC

Печалби

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

7.04.2026 г., 14:24 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

7.04.2026 г., 12:53 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

8.05.2026 г., 08:10 ч. UTC

Печалби

Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost. -- Barrons.com

8.05.2026 г., 08:08 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7.05.2026 г., 22:33 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7.05.2026 г., 21:09 ч. UTC

Печалби

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7.05.2026 г., 20:51 ч. UTC

Печалби

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7.05.2026 г., 20:06 ч. UTC

Печалби

Gilead Sciences Raises 2026 View To Sales $30B-$30.4B >GILD

7.05.2026 г., 20:05 ч. UTC

Печалби

Gilead Sciences Sees 2026 Adj Loss/Shr 65c-Adj Loss/Shr $1.05 >GILD

7.05.2026 г., 20:05 ч. UTC

Печалби

Gilead Sciences Sees 2026 Loss/Shr $2.85-Loss $3.25 >GILD

7.05.2026 г., 20:02 ч. UTC

Печалби

Gilead Sciences: Biktarvy Sales Increased 7% Yr-Over-Yr to $3.4B >GILD

7.05.2026 г., 20:01 ч. UTC

Печалби

Gilead Sciences 1Q Rev $6.96B >GILD

7.05.2026 г., 20:01 ч. UTC

Печалби

Gilead Sciences 1Q Adj EPS $2.03 >GILD

7.05.2026 г., 20:01 ч. UTC

Печалби

Gilead Sciences 1Q Total Liver Disease Sales $767M >GILD

7.05.2026 г., 20:01 ч. UTC

Печалби

Gilead Sciences 1Q EPS $1.61 >GILD

28.04.2026 г., 12:45 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

17.04.2026 г., 12:32 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

17.04.2026 г., 12:30 ч. UTC

Придобивния, сливания и поглъщания

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

7.04.2026 г., 14:36 ч. UTC

Придобивния, сливания и поглъщания

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

7.04.2026 г., 14:35 ч. UTC

Придобивния, сливания и поглъщания

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

7.04.2026 г., 14:34 ч. UTC

Придобивния, сливания и поглъщания

EQT Life Sciences: Gilead Will Also Buy TUB-030

7.04.2026 г., 14:28 ч. UTC

Придобивния, сливания и поглъщания

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

7.04.2026 г., 14:23 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Gilead Buying Another Cancer-Drug Partner -- Market Talk

7.04.2026 г., 13:55 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

7.04.2026 г., 13:14 ч. UTC

Придобивния, сливания и поглъщания

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

7.04.2026 г., 12:30 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

7.04.2026 г., 12:30 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

7.04.2026 г., 12:30 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

7.04.2026 г., 12:30 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences: Tubulis Deal Includes $3.15B Upfront Cash Consideration on Cash-Free, Debt-Free Basis >GILD

Сравнение с други в отрасъла

Ценова промяна

Gilead Sciences Inc. Прогноза

Ценова цел

By TipRanks

23.34% нагоре

12-месечна прогноза

Среден 159.83 USD 23.34%

Висок 180 USD

Нисък 122 USD

Според 22 анализатори от Wall Street, предложили 12-месечна ценова цел за Gilead Sciences Inc. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

22 ratings

Купи

Задържане

Продай

Според 22 анализатори, дали борсови рейтинги на Gilead Sciences Inc. през последните 3 месеца.

Техническа оценка

By Trading Central

97.33 / 103.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

There is one bullish event.

Настроение

By Acuity

48 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.